- cafead   Jan 26, 2023 at 10:42: AM
via Ocuphire Pharma’s diabetic retinopathy (DR) candidate missed the primary endpoint of a phase 2 trial, sending the company’s shares down over 25%. But the biotech has suggested that the drug’s effect on both eyes could still offer a path to FDA approval.
article source
article source